Pa Shun International Holdings Limited (0574) AI Stock Analysis

• Market Cap: HK$87.02M
• Dividend Yield: N/A
• Average Volume (3M): 1.15M
• Price to Earnings (P/E): ―
• Beta (1Y): -0.32
• Revenue Growth: -9.71%
• EPS Growth: -279.92%
• Country: HK
• Employees: 97
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Pharmaceuticals
• EPS (TTM): >-0.01
• Shares Outstanding: 1,474,992,900
• 10 Day Avg. Volume: 798,200
• 30 Day Avg. Volume: 1,152,533
• PEG Ratio: <0.01
• Price to Book (P/B): -0.48
• Price to Sales (P/S): 0.75
• P/FCF Ratio: -36.62
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Hold
• Number of Analyst Covering: 0

• Rating: 44 Neutral
• Price Target: HK$0.00 ▼(-100.00% Downside)

The overall stock score is primarily influenced by the company's poor financial performance, which is the most significant factor. Technical analysis provides some positive signals, but these are not strong enough to outweigh the financial challenges. The valuation is also weak due to negative earnings and lack of dividends. The absence of earnings call and corporate events data means these factors do not contribute to the score.

Pa Shun International Holdings Limited Business Overview & Revenue Model

Company Description

Pa Shun International Holdings Limited, an investment holding company, engages in the pharmaceutical distribution activities in the People's Republic of China. It operates through three segments: Pharmaceutical Distribution, Self-Operated Retail Pharmacies, and Pharmaceutical Manufacturing. The Pharmaceutical Distribution segment sells pharmaceutical products to wholesalers, franchise retail pharmacy chain stores, and hospitals and other medical institutions in rural areas. The Self-Operated Retail Pharmacies segment engages in the sale of pharmaceutical and healthcare products, cosmetic products, and daily necessities in self-operated retail pharmacies. The Pharmaceutical Manufacturing segment sells pharmaceutical products manufactured by the company. The company was formerly known as Pa Shun Pharmaceutical International Holdings Limited and changed its name to Pa Shun International Holdings Limited in June 2017. The company was incorporated in 2011 and is based in San Po Kong, Hong Kong. Pa Shun International Holdings Limited is a subsidiary of Praise Treasure Limited.

How the Company Makes Money

Pa Shun International Holdings Limited generates revenue through multiple streams, primarily from the sale of its manufactured consumer goods, including electronics and home appliances. The company operates on a business model that involves designing, producing, and distributing these products to various retailers and wholesalers both domestically and internationally. Key revenue streams include direct sales to retailers, bulk orders from distributors, and partnerships with international brands for private label manufacturing. Additionally, the company may benefit from value-added services such as after-sales support and warranty services, enhancing customer loyalty and driving repeat business. Strategic partnerships with suppliers and logistics companies also play a crucial role in optimizing operational efficiency and cost management, further contributing to its profitability.

Pa Shun International Holdings Limited Financial Statement Overview

Summary

Pa Shun International Holdings Limited is facing significant financial challenges across all verticals. The income statement reveals declining revenues and persistent losses, while the balance sheet shows negative equity and high leverage. Cash flow analysis indicates poor cash generation and sustainability issues. The company needs strategic restructuring to improve its financial health.

Income Statement

The company has experienced significant revenue decline over the years, with a notable drop from 2019 to 2024. Gross profit margins have been volatile, and the net profit margin has been negative in recent years, indicating ongoing losses. The EBIT and EBITDA margins are also negative, reflecting operational inefficiencies and financial challenges.

Balance Sheet

The balance sheet shows a concerning financial position with negative stockholders' equity, indicating potential insolvency risks. The debt-to-equity ratio cannot be calculated due to negative equity, but high total liabilities relative to assets suggest significant leverage. The equity ratio is negative, further highlighting financial instability.

Cash Flow

The company has consistently reported negative free cash flow, indicating cash outflows exceed inflows from operations. The operating cash flow to net income ratio is negative, reflecting poor cash generation relative to net losses. The free cash flow to net income ratio is also negative, underscoring cash flow challenges.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	86.55M	129.43M	71.78M	85.91M	474.83M
Gross Profit	17.06M	29.43M	13.30M	11.06M	17.70M
EBITDA	2.89M	19.65M	-3.26M	-11.85M	-11.10M
Net Income	-15.31M	2.35M	-43.38M	-330.40M	-419.19M
Balance Sheet
Total Assets	179.65M	206.57M	136.09M	468.59M	503.19M
Cash, Cash Equivalents and Short-Term Investments	15.97M	16.51M	1.90M	2.27M	5.26M
Total Debt	44.03M	165.97M	108.71M	99.01M	102.71M
Total Liabilities	315.68M	322.67M	251.60M	251.59M	225.20M
Stockholders Equity	-136.04M	-116.10M	-115.52M	-58.50M	277.98M
Cash Flow
Free Cash Flow	-1.77M	-35.00M	-2.35M	-22.12M	-6.59M
Operating Cash Flow	-1.68M	-34.93M	-2.32M	-21.89M	-6.51M
Investing Cash Flow	-88.00K	-65.00K	2.98M	24.97M	-2.43M
Financing Cash Flow	1.23M	49.61M	-1.02M	-6.07M	3.17M

Pa Shun International Holdings Limited Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.06
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:0574, the sentiment is Negative. The current price of 0.06 is above the 20-day moving average (MA) of 0.06, above the 50-day MA of 0.05, and above the 200-day MA of 0.04, indicating a neutral trend. The MACD of <0.01 indicates Positive momentum. The RSI at 40.85 is Neutral, neither overbought nor oversold. The STOCH value of 29.63 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:0574.

Pa Shun International Holdings Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
0401	―	HK$75.07M	-11.36	-9.43%	―	-10.71%	83.45%
8307	―	HK$71.41M	―	-44.60%	―	-8.20%	-10.39%
0911	―	HK$56.76M	―	-2.40%	―	-40.37%	-112.64%
Sector *	―	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
0574	―	HK$87.02M	-1.34	―	―	-9.71%	-279.92%

Pa Shun International Holdings Limited Corporate Events

Pa Shun International Announces Interim Results for H1 2025

Pa Shun International Holdings Limited, incorporated in the Cayman Islands, has announced its unaudited condensed consolidated interim results for the six months ending June 30, 2025. The announcement complies with the listing rules of the Hong Kong Stock Exchange. This release provides stakeholders with insights into the company’s financial performance and strategic positioning in the market.

Pa Shun International Issues Profit Warning for First Half of 2025

Pa Shun International Holdings Limited, listed on the Hong Kong Stock Exchange, has issued a profit warning for the six months ending 30 June 2025. The company expects to report a net loss of up to RMB10 million, a significant decline from the RMB35 million net profit recorded in the same period of the previous year. This change is primarily attributed to the absence of a one-off gain from debt restructuring that was present in the previous year’s results. The company advises shareholders and potential investors to exercise caution and await the final interim results, which are subject to adjustments and expected to be released around 11 August 2025.